Patents by Inventor Gary A. Flynn

Gary A. Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
    Patent number: 9248131
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: February 2, 2016
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter
  • IRE-1? inhibitors
    Patent number: 9241942
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: January 26, 2016
    Assignee: MannKind Corporation
    Inventors: John Bruce Patterson, David Gregory Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
    Patent number: 9221805
    Abstract: The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 29, 2015
    Assignee: Spacefill Enterprises LLP
    Inventor: Gary A. Flynn
  • INTRACELLULAR KINASE INHIBITORS
    Publication number: 20150290200
    Abstract: Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 15, 2015
    Inventors: Gary A. Flynn, Sandra A. Lee, Mary Faris, David W. Brandt, Subrata Chakravarty
  • MULTIPLE KINASE PATHWAY INHIBITORS
    Publication number: 20150266870
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Application
    Filed: September 25, 2013
    Publication date: September 24, 2015
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE
    Publication number: 20150224108
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Application
    Filed: April 3, 2015
    Publication date: August 13, 2015
    Inventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter
  • Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
    Patent number: 8987309
    Abstract: A 2-aryl-pyridylazole compound and derivatives useful in slowing the growth of cancer cells are disclosed. Also disclosed are methods of synthesizing the compound, methods of using pharmaceutical compositions containing the compound as an ingredient to slow the growth of cancer cells, and methods of treating cancer patients with pharmaceutical compositions containing the compound as an ingredient.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: March 24, 2015
    Assignees: The Translational Genomics Research Institute, The Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Robert Dorr, Gary Flynn, Haiyong Han, Laurence Hurley, Arthur Y. Shaw
  • Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
    Patent number: 8835491
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: September 16, 2014
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Gary A Flynn, Andrea J Yool, Elton Rodrigues Migliati, Leslie S Ritter
  • PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
    Publication number: 20140228367
    Abstract: The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.
    Type: Application
    Filed: February 5, 2014
    Publication date: August 14, 2014
    Inventor: Gary A. Flynn
  • AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE
    Publication number: 20140094455
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Application
    Filed: August 19, 2013
    Publication date: April 3, 2014
    Applicant: ARIZONA BOARD OF REAGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter
  • IRE-1alpha INHIBITORS
    Publication number: 20140080832
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 20, 2014
    Applicant: MANNKIND CORPORATION
    Inventors: John Bruce PATTERSON, David Gregory LONERGAN, Gary A. FLYNN, Qingping ZENG, Peter V. PALLAI
  • INTRACELLULAR KINASE INHIBITORS
    Publication number: 20140080833
    Abstract: Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.
    Type: Application
    Filed: November 11, 2013
    Publication date: March 20, 2014
    Applicant: MannKind Corporation
    Inventors: Gary A. Flynn, Sandra A. Lee, Mary Faris, David W. Brandt, Subrata Chakravarty
  • IRE-1? inhibitors
    Patent number: 8614253
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 24, 2013
    Assignee: MannKind Corporation
    Inventors: John Bruce Patterson, David Gregory Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • Intracellular kinase inhibitors
    Patent number: 8604031
    Abstract: Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: December 10, 2013
    Assignee: MannKind Corporation
    Inventors: Gary A. Flynn, Sandra Aeyoung Lee, Mary Faris, David William Brandt, Subrata Chakravarty
  • Methods, compounds and compositions with genotype selective anticancer activity
    Patent number: 8394742
    Abstract: This invention is directed to methods for screening and identification of compounds capable of selectively eliminating cancer cells with specific loss-of-function alterations, including but not limited to mutations, deletions, hypermethylations, and other types of gene silencing. This invention is also directed to novel compounds that selectively eliminate cancer cells with specific loss-of-function alterations. Furthermore, this invention is directed to methods for production and therapeutic use of compounds that selectively eliminate cancer cells with specific loss-of-function alterations.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: March 12, 2013
    Assignees: The Translation Genomics Research Institute, The Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Daniel D. Von Hoff, Haiyong Han, Hong Wang, Gary A. Flynn
  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 2-ARYL PYRIDYLAZOLES
    Publication number: 20120136029
    Abstract: A 2-aryl-pyridylazole compound and derivatives useful in slowing the growth of cancer cells are disclosed. Also disclosed are methods of synthesizing the compound, methods of using pharmaceutical compositions containing the compound as an ingredient to slow the growth of cancer cells, and methods of treating cancer patients with pharmaceutical compositions containing the compound as an ingredient.
    Type: Application
    Filed: April 19, 2010
    Publication date: May 31, 2012
    Applicants: UNIVERSITY OF ARIZONA, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Robert Dorr, Gary Flynn, Haiyong Han, Laurence Hurley
  • INTRACELLULAR KINASE INHIBITORS
    Publication number: 20110281850
    Abstract: Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.
    Type: Application
    Filed: July 7, 2011
    Publication date: November 17, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: Gary A. Flynn, Sandra Aeyoung Lee, Mary Faris, David William Brandt, Subrata Chakravarty
  • AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE
    Publication number: 20110172195
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Application
    Filed: March 15, 2011
    Publication date: July 14, 2011
    Applicant: ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ
    Inventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter
  • IRE-1alpha INHIBITORS
    Publication number: 20110065162
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 17, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: JOHN B. PATTERSON, DAVID G. LONERGAN, GARY A. FLYNN, QINGPING ZENG, PETER V. PALLAI
  • Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
    Patent number: 7906555
    Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 15, 2011
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter